Physician profile
Hong Ye
NPI 1376595710
$10,158.18
in general payments reported to CMS, 2019-2025
24 companies · $2,554 in 2025
The $2,554 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $604 · 2020: $1,706 · 2021: $419 · 2022: $784 · 2023: $922 · 2024: $3,170 · 2025: $2,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,646.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,477.55 | 2019-2025 | Vemlidy, Livdelzi |
| Glaxosmithkline, LLC. | $1,244.68 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $872.81 | 2023-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $639.23 | 2020-2025 | Breztri, Airsupra |
| Amgen INC. | $601.85 | 2021-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $399.15 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $367.85 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $302.97 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $275.00 | 2024 | Voquezna |
| Angiodynamics, INC. | $260.48 | 2024 | Angiodynamics, Nanoknife |
| Madrigal Pharmaceuticals | $252.01 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $235.54 | 2022-2025 | |
| Abbvie INC. | $204.64 | 2021-2024 | |
| Abbott Laboratories | $136.15 | 2022 | |
| Medtronic, INC. | $135.29 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $124.76 | 2025 | Camzyos |
| Axsome Therapeutics, INC. | $120.18 | 2025 | Symbravo |
| Amarin Pharma, INC. | $109.95 | 2019-2021 | |
| Pfizer INC. | $90.81 | 2021-2025 | |
| Phadia US INC. | $73.16 | 2019-2024 | Immunocap |
| Hologic Sales and Service, LLC | $52.49 | 2023-2025 | Aptima |
| Kowa Pharmaceuticals America, INC. | $38.40 | 2025 | Zoryve |
| Esperion Therapeutics, INC. | $18.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hong Ye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.